Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Caelum Biosciences, Patheon Ink Bio Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Caelum Biosciences, Patheon Ink Bio Mfg. Pact

To provide process development and cGMP production of Caelum’s lead therapy

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Fortress Biotech, Inc.’s subsidiary Caelum Biosciences, has entered a biopharmaceutical manufacturing agreement with Patheon for process development and current good manufacturing practices (cGMP) production of Caelum’s lead therapy CAEL-101.  

The agreement will support Phase II/III studies of CAEL-101 for the treatment of amyloid light chain (“AL”) amyloidosis, a rare systemic disorder that leads to the buildup of amyloid proteins in and around tissues, nerves and organs, resulting in organ damage and high mortality rates. CAEL-101 is currently being evaluated by study sponsor Columbia University in a Phase 1b study in AL amyloidosis.

Michael Spector, chief executive officer of Caelum, said, “We believe this manufacturing agreement with Patheon will enable continued progression of the CAEL-101 clinical development program. The establishment of this important collaboration, now allows us to plan for our Phase 2/3 program.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics